DE69930158D1 - Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich - Google Patents

Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich

Info

Publication number
DE69930158D1
DE69930158D1 DE69930158T DE69930158T DE69930158D1 DE 69930158 D1 DE69930158 D1 DE 69930158D1 DE 69930158 T DE69930158 T DE 69930158T DE 69930158 T DE69930158 T DE 69930158T DE 69930158 D1 DE69930158 D1 DE 69930158D1
Authority
DE
Germany
Prior art keywords
crystalline condition
metastabiles
amorph
particles
producing particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69930158T
Other languages
English (en)
Other versions
DE69930158T2 (de
Inventor
Mikael Bisrat
Saeed Moshashee
Hakan Nyqvist
Mustafa Demirbueker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE69930158D1 publication Critical patent/DE69930158D1/de
Publication of DE69930158T2 publication Critical patent/DE69930158T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Recrystallisation Techniques (AREA)
  • Saccharide Compounds (AREA)
DE69930158T 1998-11-23 1999-11-22 Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich Expired - Lifetime DE69930158T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9804000A SE9804000D0 (sv) 1998-11-23 1998-11-23 New composition of matter
SE9804000 1998-11-23
PCT/SE1999/002154 WO2000030614A1 (en) 1998-11-23 1999-11-22 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state

Publications (2)

Publication Number Publication Date
DE69930158D1 true DE69930158D1 (de) 2006-04-27
DE69930158T2 DE69930158T2 (de) 2006-11-16

Family

ID=20413377

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69930158T Expired - Lifetime DE69930158T2 (de) 1998-11-23 1999-11-22 Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich

Country Status (27)

Country Link
US (1) US6475524B1 (de)
EP (1) EP1133285B1 (de)
JP (1) JP4447169B2 (de)
KR (1) KR100697780B1 (de)
CN (1) CN1198592C (de)
AT (1) ATE318583T1 (de)
AU (1) AU767313B2 (de)
BR (1) BR9915592A (de)
CA (1) CA2349633C (de)
CY (1) CY1105609T1 (de)
CZ (1) CZ20011778A3 (de)
DE (1) DE69930158T2 (de)
DK (1) DK1133285T3 (de)
EE (1) EE200100275A (de)
ES (1) ES2258865T3 (de)
HU (1) HUP0104182A2 (de)
IL (2) IL143040A0 (de)
IS (1) IS5946A (de)
NO (1) NO20012514L (de)
NZ (1) NZ511494A (de)
PL (1) PL348523A1 (de)
PT (1) PT1133285E (de)
SE (1) SE9804000D0 (de)
SK (1) SK7032001A3 (de)
TR (1) TR200101424T2 (de)
WO (1) WO2000030614A1 (de)
ZA (1) ZA200103946B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016002D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DE10062712A1 (de) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden
US20040052854A1 (en) * 2000-12-26 2004-03-18 Tomohiro Yoshinari Porous substances and methods for producing the same
EP1401563B2 (de) * 2001-07-02 2015-09-16 Micro & Nano Materials SAGL Verfahren zur herstellung von nano- und mikro-teilchen
GB0126716D0 (en) * 2001-11-07 2002-01-02 Advanced Phytonics Ltd Method for the production of particles
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
RU2006132043A (ru) * 2004-02-06 2008-03-20 МЕДА Фарма ГмбХ унд Ко.КГ (DE) Комбинация и фармацевтический препарат для лечения ринита
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US8134010B2 (en) 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
WO2005105765A1 (en) 2004-05-05 2005-11-10 Renopharm Ltd. Nitric oxide donors and uses thereof
US7498445B2 (en) 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
US7968575B2 (en) 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
EP1833822A2 (de) 2004-08-16 2007-09-19 Theravance, Inc. Verbindungen mit beta2 adrenerg-rezeptor agonistischer und muscarin-rezeptor antagonistischer aktivität
JP5000095B2 (ja) * 2005-03-11 2012-08-15 花王株式会社 有機結晶粒子の製造方法
EP1904219A4 (de) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc Teilchenbildungsverfahren
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2009047935A1 (ja) * 2007-10-12 2009-04-16 Ono Pharmaceutical Co., Ltd. 微粒子
JP2011507676A (ja) * 2007-12-07 2011-03-10 エクスプレイ ミクロパーティクルズ アクティエボラーグ 粒子を生成する方法と構造
JP5138670B2 (ja) * 2009-01-30 2013-02-06 三洋化成工業株式会社 樹脂粒子およびその製造方法
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
CA2765621C (en) 2009-07-15 2018-02-13 Theravance, Inc. Crystalline freebase forms of a biphenyl compound
BR112012022209A2 (pt) 2010-03-03 2017-06-06 Neonc Tech Inc composições farmacêuticas compreendendo monoterpenos
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
ES2610425T3 (es) 2010-08-27 2017-04-27 Neonc Technologies Inc. Composiciones farmacéuticas que comprenden carbamatos de alcohol perilílico
CN105616391B (zh) 2010-12-17 2021-03-19 尼昂克技术公司 使用异紫苏醇的方法和装置
WO2014140648A1 (en) 2013-03-15 2014-09-18 Verona Pharma Plc Drug combination
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
SI3231444T1 (sl) 2014-05-12 2020-04-30 Verona Pharma Plc Novo zdravljenje
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
JP7144411B2 (ja) 2016-11-30 2022-09-29 ネオンク テクノロジーズ インク． ペリリルアルコール－３－ブロモピルベート複合体及びがんの治療方法
JP7325425B2 (ja) 2018-02-08 2023-08-14 ネオンク テクノロジーズ インク． 血液脳関門を透過性にする方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101090D0 (sv) 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5639441A (en) 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
WO1996029998A1 (en) 1995-03-28 1996-10-03 Fidia Advanced Biopolymers S.R.L. Nanospheres comprising a biocompatible polysaccharide
EP0969816B1 (de) 1997-03-20 2004-12-15 Schering Corporation Herstellung von pulveragglomeraten

Also Published As

Publication number Publication date
DE69930158T2 (de) 2006-11-16
CZ20011778A3 (cs) 2001-08-15
SE9804000D0 (sv) 1998-11-23
CN1198592C (zh) 2005-04-27
JP2002530319A (ja) 2002-09-17
CY1105609T1 (el) 2010-07-28
HUP0104182A2 (hu) 2002-03-28
EP1133285A1 (de) 2001-09-19
IS5946A (is) 2001-05-18
TR200101424T2 (tr) 2001-12-21
AU2010400A (en) 2000-06-13
WO2000030614A1 (en) 2000-06-02
ATE318583T1 (de) 2006-03-15
CN1328447A (zh) 2001-12-26
BR9915592A (pt) 2001-08-07
SK7032001A3 (en) 2001-11-06
KR20010080534A (ko) 2001-08-22
NO20012514L (no) 2001-07-19
CA2349633C (en) 2009-06-02
PL348523A1 (en) 2002-06-03
PT1133285E (pt) 2006-06-30
EP1133285B1 (de) 2006-03-01
NO20012514D0 (no) 2001-05-22
US6475524B1 (en) 2002-11-05
IL143040A0 (en) 2002-04-21
NZ511494A (en) 2003-11-28
KR100697780B1 (ko) 2007-03-21
CA2349633A1 (en) 2000-06-02
DK1133285T3 (da) 2006-06-06
AU767313B2 (en) 2003-11-06
ES2258865T3 (es) 2006-09-01
EE200100275A (et) 2002-10-15
IL143040A (en) 2009-09-01
ZA200103946B (en) 2002-10-30
JP4447169B2 (ja) 2010-04-07

Similar Documents

Publication Publication Date Title
DE69930158D1 (de) Verfahren zur herstellung von partikeln mit einem aus dem amorphen und/oder metastabilen kristallinen zustand in einen kristallinen zustand überführten bereich
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
FI961438A (fi) beta-amyloidiproteiinituotannon estäjiä
DE69920946D1 (de) Verfahren zur herstellung kristalliner partikel
EP1095656A3 (de) Pharmazeutische Zubereitung mit dem Cholinesterase-Hemmstoff Galanthamin
ATE327763T1 (de) Pflanzenextrakte und deren anwendung
DE60310605D1 (de) Nanoteilchen zur verabreichung von wirkstoffen, verfahren zur herstellung dieser teilchen und diese enthaltende zusammensetzung
CA2501738A1 (en) Method of treating chronic pelvic pain syndrome by administration of chrorionic gonadotropin
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
DE69005557D1 (de) Substituierte 4-Amino-2-butinyl-Harnstoffe und -thioharnstoffe sowie deren Derivate als zentral wirkende muscarinische Mittel.
ATE437641T1 (de) Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid- neurotoxizität und mikrogliosis
ATE402253T1 (de) Humane adulte astrozyten, sowie deren herstellung und verwendung
ATE304861T1 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
Springer et al. Dopamine depletion in nucleus accumbens reduces ACTH1–24-induced excessive grooming
WO2002076437A3 (en) Methods for treating neurodegenerative diseases including alzheimer's
DE69810906T2 (de) Optisch aktive 2-amino-tetraline, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten und die nützlich sind zur vorbeugung und behandlung von septischem schock
WO2005007169A3 (en) Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
PT66339A (de) 1,2,3-thiadiazol-5-yl-harnstoffe,verfahren zur herstellung dieser verbindungen sowie diese enthaltende mittel zur wachstumsverzoegerung und zur entblaetterung von pflanzen
DE69433923D1 (de) Salbe enthaltend mometason-furoat und salicylsäure zur topischen behandlung von psoriasis
ATE275953T1 (de) 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis
WO2004012710A8 (en) Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
WO2004033472A8 (de) Verfahren zur herstellung von monomeren uronsäuren, insbesondere d-mannuronsäure und d-guluronsäure, derivaten davon und deren verwendung als arzneimittel
WO2002096444A3 (de) Zusammensetzung mit therapeutischer wirksamkeit
RU93044740A (ru) Гетероциклические соединения, способ их получения, применение и фармацевтическая композиция

Legal Events

Date Code Title Description
8364 No opposition during term of opposition